KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Capital Expenditures: 2013-2025

Historic Capital Expenditures for Travere Therapeutics (TVTX) over the last 11 years, with Sep 2025 value amounting to $140,000.

  • Travere Therapeutics' Capital Expenditures was N/A to $140,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $257,000, marking a year-over-year change of. This contributed to the annual value of $668,000 for FY2023, which is 249.74% up from last year.
  • Latest data reveals that Travere Therapeutics reported Capital Expenditures of $140,000 as of Q3 2025, which was up 70.73% from $82,000 recorded in Q2 2024.
  • In the past 5 years, Travere Therapeutics' Capital Expenditures ranged from a high of $4.5 million in Q1 2021 and a low of $3,000 during Q2 2023.
  • Over the past 3 years, Travere Therapeutics' median Capital Expenditures value was $53,500 (recorded in 2023), while the average stood at $148,333.
  • Per our database at Business Quant, Travere Therapeutics' Capital Expenditures slumped by 97.09% in 2022 and then soared by 2,633.33% in 2024.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Capital Expenditures stood at $154,000 in 2021, then tumbled by 80.52% to $30,000 in 2022, then fell by 16.67% to $25,000 in 2023, then skyrocketed by 2,633.33% to $82,000 in 2024, then reached $140,000 in 2025.
  • Its Capital Expenditures stands at $140,000 for Q3 2025, versus $82,000 for Q2 2024 and $25,000 for Q4 2023.